Interim Guidance for Clinicians Considering the Use of Preexposure Prophylaxis for the Prevention of HIV Infection in Heterosexually Active Adults

Get This Resource

English: Web Page

Summary

In January 2011 studies on daily oral tenofovir as antiretroviral preexposure prophylaxis (PrEP) to reduce the risk for HIV acquisition among MSM were published and the CDC issued interim guidance for ARV prophylaxis in this population. Those recommendations remain valid for MSM, including MSM who also have sex with women. Since January 2011, data from studies of PrEP among heterosexual men and women have become available, and in July 2012, the FDA approved a label indication for reduction of risk for sexual acquisition of HIV infection among adults, including both heterosexuals and MSM. These interim recommendations address PrEP for heterosexual populations, including discussion of pregnancy and safety issues for heterosexually active adults at very high risk for sexual HIV acquisition.

Publisher:	National Center for HIV, STD and TB Prevention
Language:	English
Format:	Web Page
Region:	North America
Audiences:	Doctors/Physicians, Nurses, Other Healthcare Workers, Program Managers, Policymakers
Topic Areas:	Antiretroviral Treatment & Complications, Primary Prevention
Resource Type:	Clinical Guidelines